{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:49:37Z","timestamp":1762422577294,"version":"build-2065373602"},"reference-count":85,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2025.0173","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:42:28Z","timestamp":1762422148000},"source":"Crossref","is-referenced-by-count":0,"title":["Preventive measures for patients with an elevated genetic risk for gynecological malignancies, in particular familial breast and ovarian cancer."],"prefix":"10.3238","author":[{"given":"Nina","family":"Ditsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahriye","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maggie","family":"Banys-Paluchowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothee","family":"Speiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika M.","family":"Golas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"10.3238\/arztebl.m2025.0173_ref1","doi-asserted-by":"crossref","unstructured":"Carver T, Hartley S, Lee A, et al.: CanRisk tool\u2014a web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants. Cancer Epidemiol Biomarkers Prev 2021; 30: 469\u201373.","DOI":"10.1158\/1055-9965.EPI-20-1319"},{"key":"10.3238\/arztebl.m2025.0173_ref2","doi-asserted-by":"crossref","unstructured":"Archer S, Babb de Villiers Ch, Scheibl F, et al.: Evaluating clinician acceptability of the prototype canrisk tool for predicting risk of breast and ovarian cancer: A multi-methods study. PLoS One 2020; 6; 15: e0229999.","DOI":"10.1371\/journal.pone.0229999"},{"key":"10.3238\/arztebl.m2025.0173_ref3","doi-asserted-by":"crossref","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D, et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66\u201371.","DOI":"10.1126\/science.7545954"},{"key":"10.3238\/arztebl.m2025.0173_ref4","doi-asserted-by":"crossref","unstructured":"Wooster R, Bignell G, Lancaster J, et al.: Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789\u201392.","DOI":"10.1038\/378789a0"},{"key":"10.3238\/arztebl.m2025.0173_ref5","unstructured":"Robert Koch-Institut (eds.) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (eds.): Krebs in Deutschland f\u00fcr 2019\/2020. 2023; 14. Ausgabe."},{"key":"10.3238\/arztebl.m2025.0173_ref6","doi-asserted-by":"crossref","unstructured":"Meindl A, Ditsch N, Kast K, Rhiem K, Schmutzler RK: Hereditary breast and ovarian cancer: New genes, new treatments, new concepts. Dtsch Arztebl Int 2011; 108: 323\u201330.","DOI":"10.3238\/arztebl.2011.0323"},{"key":"10.3238\/arztebl.m2025.0173_ref7","doi-asserted-by":"crossref","unstructured":"Hauke J, Horvath J, Gro\u00df E, et al.: Gene panel testing of 5589 BRCA1\/2-negative index patients with breast cancer in a routine diagnostic setting: Results of the German consortium for hereditary breast and ovarian cancer. Cancer Med 2018; 7: 1349\u201358.","DOI":"10.1002\/cam4.1376"},{"key":"10.3238\/arztebl.m2025.0173_ref8","doi-asserted-by":"crossref","unstructured":"Pal T, Mundt E, Richardson ME, et al.: Reduced penetrance BRCA1 and BRCA2 pathogenic variants in clinical germline genetic testing. NPJ Precis Oncol 2024; 8: 247.","DOI":"10.1038\/s41698-024-00741-4"},{"key":"10.3238\/arztebl.m2025.0173_ref9","doi-asserted-by":"crossref","unstructured":"Risch HA, McLaughlin JR, Cole DE, et al.: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68: 700\u201310.","DOI":"10.1086\/318787"},{"key":"10.3238\/arztebl.m2025.0173_ref10","unstructured":"www.konsortium-familiaerer-brustkrebs.de\/konsensusempfehlung\/ (last accessed on 1 September 2025)."},{"key":"10.3238\/arztebl.m2025.0173_ref11","doi-asserted-by":"crossref","unstructured":"Southey MC, Goldgar DE, Winqvist R, et al.: PALB2, CHEK2 and ATM rare variants and cancer risk: Data from COGS. J Med Genet 2016; 53: 800\u201311.","DOI":"10.1136\/jmedgenet-2016-103839"},{"key":"10.3238\/arztebl.m2025.0173_ref12","doi-asserted-by":"crossref","unstructured":"Milne RL, Kuchenbaecker KB, Michailidou K, et al.: Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet 2017; 49: 1767\u201378.","DOI":"10.1038\/ng.3785"},{"key":"10.3238\/arztebl.m2025.0173_ref13","doi-asserted-by":"crossref","unstructured":"Fachal L, Aschard H, Beesley J, et al.: Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nat Genet 2020; 52: 56\u201373.","DOI":"10.1038\/s41588-019-0537-1"},{"key":"10.3238\/arztebl.m2025.0173_ref14","doi-asserted-by":"crossref","unstructured":"Ghoussaini M, Fletcher O, Michailidou K, et al.: Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 2012; 44: 312\u20138.","DOI":"10.1038\/ng.1049"},{"key":"10.3238\/arztebl.m2025.0173_ref15","doi-asserted-by":"crossref","unstructured":"Mavaddat N, Michailidou K, Dennis J, et al.: Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet 2019; 104: 21\u201334.","DOI":"10.1016\/j.ajhg.2018.11.002"},{"key":"10.3238\/arztebl.m2025.0173_ref16","doi-asserted-by":"crossref","unstructured":"Michailidou K, Beesley J, Lindstrom S, et al.: Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet 2015; 47: 373\u201380.","DOI":"10.1038\/ng.3242"},{"key":"10.3238\/arztebl.m2025.0173_ref17","unstructured":"Michailidou K, Hall P, Gonzalez-Neira A, et al.: Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013; 45: 353\u201361, 361e1\u20132."},{"key":"10.3238\/arztebl.m2025.0173_ref18","doi-asserted-by":"crossref","unstructured":"Michailidou K, Lindstr\u00f6m S, Dennis J, et al.: Association analysis identifies 65 new breast cancer risk loci. Nature 2017; 551: 92\u20134.","DOI":"10.1038\/nature24284"},{"key":"10.3238\/arztebl.m2025.0173_ref19","unstructured":"Kuchenbaecker et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers JAMA 2017. PMID: 28632866."},{"key":"10.3238\/arztebl.m2025.0173_ref20","doi-asserted-by":"crossref","unstructured":"Tai YC, Domchek S, Parmigiani G, Chen S: Breast cancer risk amongmale BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2007; 99: 1811\u20134.","DOI":"10.1093\/jnci\/djm203"},{"key":"10.3238\/arztebl.m2025.0173_ref21","doi-asserted-by":"crossref","unstructured":"Antoniou AC, Casadei S, Heikkinen T, et al.: Breast-cancer risk in families with mutations in PALB2. N Engl J Med 2014; 371: 497\u2013506.","DOI":"10.1056\/NEJMc1410673"},{"key":"10.3238\/arztebl.m2025.0173_ref22","unstructured":"Schneider K, Zelley K, Nichols KE, et al.: Li-Fraumeni syndrome. Editors. In: GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993.1999 Jan 19 [updated 2025 May 1]."},{"key":"10.3238\/arztebl.m2025.0173_ref23","doi-asserted-by":"crossref","unstructured":"Loveday C, Turnbull C, Ruark E, et al.: Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet 2012; 44: 475\u20136; author reply 476.","DOI":"10.1038\/ng.2224"},{"key":"10.3238\/arztebl.m2025.0173_ref24","doi-asserted-by":"crossref","unstructured":"Loveday C, Turnbull C, Ramsay E, et al.: Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 2011; 43: 879\u201382.","DOI":"10.1038\/ng.893"},{"key":"10.3238\/arztebl.m2025.0173_ref25","doi-asserted-by":"crossref","unstructured":"Suszynska M, Ratajska M, Kozlowski P: BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: Mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases. J Ovarian Res 2020; 13: 50.","DOI":"10.1186\/s13048-020-00654-3"},{"key":"10.3238\/arztebl.m2025.0173_ref26","unstructured":"Deutsche Krebsgesellschaft: Checkliste zur Erfassung einer m\u00f6glichen erblichen Belastung f\u00fcr Brust- und\/oder Eierstockkrebs. 2025."},{"key":"10.3238\/arztebl.m2025.0173_ref27","doi-asserted-by":"crossref","unstructured":"Park-Simon TW, M\u00fcller V, Albert US, et al.: AGO recommendations for the diagnosis and treatment of patients with early breast cancer: Update 2025. Breast Care (Basel). 2025; 8: 1\u201319.","DOI":"10.1159\/000545019"},{"key":"10.3238\/arztebl.m2025.0173_ref28","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms. https:\/\/register.awmf.org\/assets\/guidelines\/032\u2013045OLl_S3_Mammakarzinom_2021\u201307.pdf (last accessed on 4 October 2025)."},{"key":"10.3238\/arztebl.m2025.0173_ref29","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren., https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Ovarialkarzinom\/Version_6\/LL_Ovarialkarzinom_Langversion_6.0.pdf (last accessed on 4 October 2025)"},{"key":"10.3238\/arztebl.m2025.0173_ref30","doi-asserted-by":"crossref","unstructured":"Slesina W: Primordial, primary, secondary and tertiary prevention. A definition. Dtsch Med Wochenschr 2007; 132: 2196\u20138.","DOI":"10.1055\/s-2007-991628"},{"key":"10.3238\/arztebl.m2025.0173_ref31","unstructured":"www.konsortium-familiaerer-brustkrebs.de\/ (last accessed on 01.09.2025)."},{"key":"10.3238\/arztebl.m2025.0173_ref32","doi-asserted-by":"crossref","unstructured":"Yang X, Mooij TM, Leslie G, et al.: Validation of the BOADICEA model in a prospective cohort of BRCA1\/2 pathogenic variant carriers. J Med Genet 2024; 61: 803\u20139.","DOI":"10.1136\/jmg-2024-109943"},{"key":"10.3238\/arztebl.m2025.0173_ref33","doi-asserted-by":"crossref","unstructured":"Kast K, Wimberger P, Schr\u00f6ck E, Schmutzler RK: Famili\u00e4rer Brust- und Eierstockkrebs: Zielgerichtete und abgestufte Pr\u00e4ventionsstrategien. Dtsch Arztebl 2020; 117:[33\u201334] 22.\u00a0","DOI":"10.3238\/PersOnko.2020.08.17.06"},{"key":"10.3238\/arztebl.m2025.0173_ref34","doi-asserted-by":"crossref","unstructured":"Sessa C, Balma\u00f1a J, Bober SL, et al.: Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol 2023; 34: 33\u201347.","DOI":"10.1016\/j.annonc.2022.10.004"},{"key":"10.3238\/arztebl.m2025.0173_ref35","doi-asserted-by":"crossref","unstructured":"Carbine NE, Lostumbo L, Wallace J, Ko H: Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Revs 2018; 4: CD002748.","DOI":"10.1002\/14651858.CD002748.pub4"},{"key":"10.3238\/arztebl.m2025.0173_ref36","doi-asserted-by":"crossref","unstructured":"De Felice F, Marchetti C: Risk-reducing surgery in BRCA 1\/2 mutation carries: A point of view. Oncotarget 2015; 6: 39391\u20132.","DOI":"10.18632\/oncotarget.6348"},{"key":"10.3238\/arztebl.m2025.0173_ref37","unstructured":"Nelson HD, Fu R, Goddard K, et al.: Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: Systematic review to update the U.S. preventive services task force recommendation. Agency for Healthcare Research and Quality (US); 2013 Dec. Report No.: 12\u201305164-EF-1."},{"key":"10.3238\/arztebl.m2025.0173_ref38","doi-asserted-by":"crossref","unstructured":"Schrag D, Kuntz KM, Garber JE, et al.: Decision analysis\u2014effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997; 336: 1465\u201371.","DOI":"10.1056\/NEJM199705153362022"},{"key":"10.3238\/arztebl.m2025.0173_ref39","unstructured":"www.ago-online.de\/leitlinien-empfehlungen\/leitlinien-empfehlungen\/kommission-mamma; Brustkrebsrisiko, Genetik und Pr\u00e4vention (last accessed on 01 September 2025)."},{"key":"10.3238\/arztebl.m2025.0173_ref40","doi-asserted-by":"crossref","unstructured":"Heemskerk-Gerritsen BAM, Jager A, Koppert LB, et al.: Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2019; 177: 723\u201333.","DOI":"10.1007\/s10549-019-05345-2"},{"key":"10.3238\/arztebl.m2025.0173_ref41","unstructured":"www.brca-netzwerk.de (last accessed on 1 September 2025)."},{"key":"10.3238\/arztebl.m2025.0173_ref42","doi-asserted-by":"crossref","unstructured":"Marchetti C, De Felice F, Palaia I, et al.: Risk-reducing salpingo-oophorectomy: A meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Women\u2018s Health 2014; 14: 150.","DOI":"10.1186\/s12905-014-0150-5"},{"key":"10.3238\/arztebl.m2025.0173_ref43","doi-asserted-by":"crossref","unstructured":"Kotsopoulos J, Narod SA: Prophylactic salpingectomy for the prevention of ovarian cancer: Who should we target? Int J Cancer 2020; 147: 1245\u201351.","DOI":"10.1002\/ijc.32916"},{"key":"10.3238\/arztebl.m2025.0173_ref44","doi-asserted-by":"crossref","unstructured":"Cuzick J, Sestak I, Forbes JF, et al.: Use of anastrozole for breast cancer prevention (IBIS-II): Long-term results of a randomised controlled trial. Lancet (London, England) 2020; 395: 117\u201322.","DOI":"10.1016\/S0140-6736(19)32955-1"},{"key":"10.3238\/arztebl.m2025.0173_ref45","doi-asserted-by":"crossref","unstructured":"N Wolmark, Dunn BK: The role of tamoxifen in breast cancer prevention: Issues sparked by the NSABP breast cancer prevention trial (P-1). Ann N Y Acad Sci 2001: 949: 99\u2013108.","DOI":"10.1111\/j.1749-6632.2001.tb04007.x"},{"key":"10.3238\/arztebl.m2025.0173_ref46","doi-asserted-by":"crossref","unstructured":"Vogel VG, Costantino JP, Wickerham DL, et al: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727\u201341.","DOI":"10.1001\/jama.295.23.joc60074"},{"key":"10.3238\/arztebl.m2025.0173_ref47","doi-asserted-by":"crossref","unstructured":"Goss PE, Ingle JN, Al\u00e9s-Mart\u00ednez JE, et al.: Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 364: 2381\u201391.","DOI":"10.1056\/NEJMoa1103507"},{"key":"10.3238\/arztebl.m2025.0173_ref48","doi-asserted-by":"crossref","unstructured":"Forbes JF, Sestak I, Howell A, et al.: Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): A double-blind, randomised controlled trial. Lancet (London, England) 2016; 387: 866\u201373.","DOI":"10.1016\/S0140-6736(15)01129-0"},{"key":"10.3238\/arztebl.m2025.0173_ref49","doi-asserted-by":"crossref","unstructured":"Huber D, Seitz S, Kast K, Emons G, Ortmann O: Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: A systematic review. Arch Gynecol Obstet 2020; 301: 875\u201384.","DOI":"10.1007\/s00404-020-05458-w"},{"key":"10.3238\/arztebl.m2025.0173_ref50","doi-asserted-by":"crossref","unstructured":"Karlsson T, Johansson T, H\u00f6glundJ, Ek WE, Johansson \u00c5: Time-dependent effects of oral contraceptive use on breast, ovarian, and endometrial cancers. Cancer Res 2021; 81: 1153\u201362.","DOI":"10.1158\/0008-5472.CAN-20-2476"},{"key":"10.3238\/arztebl.m2025.0173_ref51","doi-asserted-by":"crossref","unstructured":"Narod SA, Dube MP, Klijn J, et al.: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002; 94: 1773\u20139.","DOI":"10.1093\/jnci\/94.23.1773"},{"key":"10.3238\/arztebl.m2025.0173_ref52","doi-asserted-by":"crossref","unstructured":"Zolfaroli I, Tar\u00edn JJ, Cano A: The action of estrogens and progestogens in the young female breast. Eur J Obstet Gynecol Reprod Biol 2018; 230: 204\u20137.","DOI":"10.1016\/j.ejogrb.2018.03.057"},{"key":"10.3238\/arztebl.m2025.0173_ref53","doi-asserted-by":"crossref","unstructured":"Singer CF: Nonsurgical prevention strategies in BRCA1 and BRCA2 mutation carriers. Breast Care (Basel) 2021; 16: 144\u20138.","DOI":"10.1159\/000507503"},{"key":"10.3238\/arztebl.m2025.0173_ref54","doi-asserted-by":"crossref","unstructured":"Isern AE, Tengrup I, Loman N, et al.: Aesthetic outcome, patient satisfaction, and health-related quality of life in women at high risk undergoing prophylactic mastectomy and immediate breast reconstruction. J Plast Reconstr Aesthet Surg 2008; 61: 1177\u201387.","DOI":"10.1016\/j.bjps.2007.08.006"},{"key":"10.3238\/arztebl.m2025.0173_ref55","doi-asserted-by":"crossref","unstructured":"Bruno E, Oliverio A, Paradiso A, et al.: Lifestyle characteristics in women carriers of BRCA mutations: Results from an Italian trial cohort. Clinical Breast cancer 2021; 21: e168\u2013e76.","DOI":"10.1016\/j.clbc.2020.11.002"},{"key":"10.3238\/arztebl.m2025.0173_ref56","doi-asserted-by":"crossref","unstructured":"Grill S, Yahiaoui-Doktor M, Dukatz R, et al.: Smoking and physical inactivity increase cancer prevalence in BRCA-1 and BRCA-2 mutation carriers: Results from a retrospective observational analysis. Arch Gynecol Obstet 2017; 296: 1135\u201344.","DOI":"10.1007\/s00404-017-4546-y"},{"key":"10.3238\/arztebl.m2025.0173_ref57","doi-asserted-by":"crossref","unstructured":"Guinan EM, Hussey J, McGarrigle SA, et al.: A prospective investigation of predictive and modifiable risk factors for breast cancer in unaffected BRCA1 and BRCA2 gene carriers. BMC Cancer 2013; 13: 138.","DOI":"10.1186\/1471-2407-13-138"},{"key":"10.3238\/arztebl.m2025.0173_ref58","doi-asserted-by":"crossref","unstructured":"Kiechle M, Engel C, Berling A, et al.: Effects of lifestyle intervention in BRCA1\/2 mutation carriers on nutrition, BMI, and physical fitness (LIBRE study): Study protocol for a randomized controlled trial. Trials 2016; 17: 368.","DOI":"10.1186\/s13063-016-1504-0"},{"key":"10.3238\/arztebl.m2025.0173_ref59","doi-asserted-by":"crossref","unstructured":"Lubinski J, Kotsopoulos J, Moller P, et al.: MRI surveillance and breast cancer mortality in women with BRCA1 and BRCA2 sequence variations. JAMA Oncol 2024; 10: e236944.","DOI":"10.1001\/jamaoncol.2023.6944"},{"key":"10.3238\/arztebl.m2025.0173_ref60","unstructured":"Leitlinienprogramm Onkologie, Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF: S3-Leitlinie Prostatakarzinom, Kurzversion 6.0. AWMF Registernummer: 043\/022OL 2021."},{"key":"10.3238\/arztebl.m2025.0173_ref61","doi-asserted-by":"crossref","unstructured":"Gaddam S, Heller SL, Babb JS, Gao Y: Male breast cancer risk assessment and screening recommendations in high-risk men who undergo genetic counseling and multigene panel testing. Clin BreastCancer 2021; 21: e74\u2013e9.","DOI":"10.1016\/j.clbc.2020.07.014"},{"key":"10.3238\/arztebl.m2025.0173_ref62","doi-asserted-by":"crossref","unstructured":"Menon U, Karpinskyj C, Gentry-Maharaj A: Ovarian cancer prevention and screening. Obstet Gynecol 2018; 131: 909\u201327.","DOI":"10.1097\/AOG.0000000000002580"},{"key":"10.3238\/arztebl.m2025.0173_ref63","doi-asserted-by":"crossref","unstructured":"Serrano D, Bonanni B, Brown K: Therapeutic cancer prevention: Achievements and ongoing challenges\u2014a focus on breast and colorectal cancer. Mol Oncol 2019; 13: 579\u201390.","DOI":"10.1002\/1878-0261.12461"},{"key":"10.3238\/arztebl.m2025.0173_ref64","doi-asserted-by":"crossref","unstructured":"Wei G, Kumar A, Lee MC, Wang X: Influential factors on risk-reduction mastectomy in a high-risk breast cancer population with genetic predispositions. Clin Breast Cancer 2021; 21: e427\u2013e33.","DOI":"10.1016\/j.clbc.2021.01.008"},{"key":"10.3238\/arztebl.m2025.0173_ref65","doi-asserted-by":"crossref","unstructured":"Heemskerk-Gerritsen BAM, Rookus MA, Aalfs CA, et al: Improved overall survival after contralateral risk-reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis. Int J Cancer 2015; 136: 668\u201377.","DOI":"10.1002\/ijc.29032"},{"key":"10.3238\/arztebl.m2025.0173_ref66","doi-asserted-by":"crossref","unstructured":"Blondeaux E, Sonnenblick A, Agostinetto E, et al.: Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: An international cohort study. Lancet Oncol 2025; 26: 759\u201370.","DOI":"10.1016\/S1470-2045(25)00152-4"},{"key":"10.3238\/arztebl.m2025.0173_ref67","doi-asserted-by":"crossref","unstructured":"Tung NM, Boughey JC, Pierce LJ, et al.: Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Onco 2020; 38: 2080\u201306.","DOI":"10.1200\/JCO.20.00299"},{"key":"10.3238\/arztebl.m2025.0173_ref68","doi-asserted-by":"crossref","unstructured":"Nara M, Ishihara S, Kitano A, et al.: Does breast-conserving surgery with radiotherapy in BRCA-mutation carriers significantly increase ipsilateral breast tumor recurrence? A systematic review and meta-analysis. Breast Cancer 2022; 29: 394\u2013401.","DOI":"10.1007\/s12282-022-01343-3"},{"key":"10.3238\/arztebl.m2025.0173_ref69","doi-asserted-by":"crossref","unstructured":"Trombetta MG, Dragun A, Mayr NA, Pierce LJ: ASTRO radiation therapy summary of the ASCO-ASTRO-SSO guideline on management of hereditary breast cancer. Pract Radiat Oncol 2020; 10: 235\u201342.","DOI":"10.1016\/j.prro.2020.04.003"},{"key":"10.3238\/arztebl.m2025.0173_ref70","doi-asserted-by":"crossref","unstructured":"Shrebati A, Loap P, Kirova Y. Adjuvant radiotherapy and breast cancer in patients with Li-Fraumeni Syndrome: A critical review. cancers (Basel). 2025; 17: 1206.","DOI":"10.3390\/cancers17071206"},{"key":"10.3238\/arztebl.m2025.0173_ref71","doi-asserted-by":"crossref","unstructured":"Thariat J, Chevalier F, Orbach D, et al.: Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes. Lancet Oncology 2021; 22: e562\u2013e74.","DOI":"10.1016\/S1470-2045(21)00425-3"},{"key":"10.3238\/arztebl.m2025.0173_ref72","doi-asserted-by":"crossref","unstructured":"Metzger-Filho O, Collier K, Asad S, et al.: Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. NPJ Breast Cancer 2021; 7: 142.","DOI":"10.1038\/s41523-021-00349-y"},{"key":"10.3238\/arztebl.m2025.0173_ref73","doi-asserted-by":"crossref","unstructured":"Farmer H, McCabe N, Lord CJ, et al.; Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917\u201321.","DOI":"10.1038\/nature03445"},{"key":"10.3238\/arztebl.m2025.0173_ref74","doi-asserted-by":"crossref","unstructured":"Bryant HE, Schultz N, Thomas HD, et al.: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913\u20137.","DOI":"10.1038\/nature03443"},{"key":"10.3238\/arztebl.m2025.0173_ref75","doi-asserted-by":"crossref","unstructured":"Tutt ANJ, Garber JE, Kaufman B, et al.: Adjuvant Olaparib for patients with BRCA1\u2013 or BRCA2-mutated breast cancer. N Eng J of Med 2021; 384: 2394\u2013405.","DOI":"10.1056\/NEJMoa2105215"},{"key":"10.3238\/arztebl.m2025.0173_ref76","doi-asserted-by":"crossref","unstructured":"Geyer CE Jr, Garber JE, Gelber RD, et al.: Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer. Ann Oncol. 2022; 33: 1250\u201368.","DOI":"10.1016\/j.annonc.2022.09.159"},{"key":"10.3238\/arztebl.m2025.0173_ref77","doi-asserted-by":"crossref","unstructured":"Garber J, Cameron D, Campbell Ch, et al.: Abstract GS1\u201309: OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w\/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer: Clinical Cancer Research 2025; 31 (12_Supplement): GS1\u201309\u2013GS1\u201309.","DOI":"10.1158\/1557-3265.SABCS24-GS1-09"},{"key":"10.3238\/arztebl.m2025.0173_ref78","doi-asserted-by":"crossref","unstructured":"Ganz PA, Bandos H, Spanic T, et al.: Patient-reported outcomes in olympiA: A phase III, randomized, placebo-controlled trial of adjuvant olaparib in gBRCA1\/2 mutations and high-risk human epidermal growth factor receptor 2-negative early breast cancer. J Clin Oncol 2024; 42: 1288\u2013300.","DOI":"10.1200\/JCO.23.01214"},{"key":"10.3238\/arztebl.m2025.0173_ref79","doi-asserted-by":"crossref","unstructured":"Penson RT, Valencia RV, Cibula D, et al.: Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1\/2 mutation (SOLO3): A randomized phase III trial. J Clin Oncol 2020; 38: 1164\u201374.","DOI":"10.1200\/JCO.19.02745"},{"key":"10.3238\/arztebl.m2025.0173_ref80","doi-asserted-by":"crossref","unstructured":"Lux MP, Fasching PA: Breast cancer and genetic BRCA1\/2 testing in routine clinical practice: Why, when and for whom? Geburtshilfe Frauenheilkd 2023; 83: 310\u201320.","DOI":"10.1055\/a-1929-2629"},{"key":"10.3238\/arztebl.m2025.0173_ref81","doi-asserted-by":"crossref","unstructured":"Emandi AC, Andreescu N, Popa C, et al.: Biallelic variants in BRCA1 gene cause a recognisable phenotype within chromosomal instability syndromes reframed as BRCA1 deficiency. J Med Genet 2021; 58: 648\u201352.","DOI":"10.1136\/jmedgenet-2020-107198"},{"key":"10.3238\/arztebl.m2025.0173_ref82","doi-asserted-by":"crossref","unstructured":"Hughes T, Rose AM: The emergence of Fanconi anaemia type S: A phenotypic spectrum of biallelic BRCA1 mutations. Front Oncol 2023; 13: 1278004.","DOI":"10.3389\/fonc.2023.1278004"},{"key":"10.3238\/arztebl.m2025.0173_ref83","doi-asserted-by":"crossref","unstructured":"McReynolds LJ, Biswas K, Giri N, Sharan SK, Alter BP: Genotype-cancer association in patients with Fanconi anemia due to pathogenic variants in FANCD1 (BRCA2) or FANCN (PALB2). Cancer Genet 2021: 258\u20139: 101\u20139.","DOI":"10.1016\/j.cancergen.2021.10.001"},{"key":"10.3238\/arztebl.m2025.0173_ref84","doi-asserted-by":"crossref","unstructured":"Bogliolo M, Surrall\u00e9s J: Fanconi anemia: A model disease for studies on human genetics and advanced therapeutics. Opin Genet Dev 2015: 33: 32\u201340.","DOI":"10.1016\/j.gde.2015.07.002"},{"key":"10.3238\/arztebl.m2025.0173_ref85","doi-asserted-by":"crossref","unstructured":"Reiman A, Srinivasan V, Barone G, et al.: Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours. Br J Cancer 2011; 105: 586\u201391.","DOI":"10.1038\/bjc.2011.266"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:44:29Z","timestamp":1762422269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":85,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2025.0173","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]}}}